RhumbLine Advisers
LUCD icon

RhumbLine Advisers’s Lucid Diagnostics LUCD Stock Holding History

RhumbLine Advisers’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90K Buy
84,083
+35,453
+73% +$38.2K ﹤0.01% 3566
2026
Q1 		$55.9K Sell
48,630
-3,877
-7% -$4.93K ﹤0.01% 3571
2025
Q4 		$57.2K Sell
52,507
-13,622
-21% -$15.2K ﹤0.01% 3612
2025
Q3 		$66.8K Buy
66,129
+3,113
+5% +$3.4K ﹤0.01% 3609
2025
Q2 		$72.5K Buy
+63,016
New +$81.4K ﹤0.01% 3614

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

RhumbLine Advisers's LUCD Position: Q2 2026 in Review

RhumbLine Advisers increased its Lucid Diagnostics (LUCD) stake by 73% in Q2 2026, buying an estimated $38.2K and bringing the position to 84,083 shares worth $90K. The position accounts for ﹤0.01% of the portfolio, ranked #3566.

RhumbLine Advisers first reported a position in LUCD in Q2 2025 and has held it in 5 quarters since. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • RhumbLine Advisers held 84,083 shares of Lucid Diagnostics worth $90K as of Q2 2026.
  • RhumbLine Advisers bought 35,453 Lucid Diagnostics shares in Q2 2026, an estimated $38.2K.
  • Lucid Diagnostics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3566 holding.
  • RhumbLine Advisers first reported a position in Lucid Diagnostics in Q2 2025 and has held it in 5 quarters since.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.